Abstract #2357

Multimodal MRI/MRS evaluation of treatment response in a patient-derived xenograft model of Ewing sarcoma

Puneet Bagga¹, Jeffrey Steinberg², Walter Akers², Matthew Scoggins¹, Zoltan Patay¹, Beth McCarville¹, Burkhard Hoeckendorf³, Khaled Khairy³, Michael Dyer³, and Beth Stewart³

¹Department of Diagnostic Imaging, St Jude Children's Research Hospital, Memphis, TN, United States, ²Center for In Vivo Imaging and Therapeutics (CIVIT), St Jude Children's Research Hospital, Memphis, TN, United States, ³Department of Developmental Neurobiology, St Jude Children's Research Hospital, Memphis, TN, United States

A recent development in multi-modality treatment with poly ADP-ribose polymerase inhibitors (PARPi’s) combined with DNA damaging agents (temozolomide), is increasingly recognized as an important approach for curing or prolonging survival in patients with recurrent Ewing sarcoma (EWS). In this study, we employed multimodal quantitative imaging methods to predict treatment response in EWS. We used T2-weighted MRI, diffusion-weighted MRI, and ¹H MRS in a patient derived xenograft model of EWS. We envisage that multi-parametric MR indices will be able to evaluate the treatment response and predict treatment response in the tumors.

This abstract and the presentation materials are available to members only; a login is required.

Join Here